Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara

Arthritis Research and Therapy

Volumn 15, Issue 2, 2013, Pages

  Petri, Marcelo H ^a   Satoh, Minoru ^b   Martin Marquez, Beatriz T ^a   Vargas Ramírez, Raul ^a   Jara, Luis J ^c   Saavedra, Miguel A ^d   Cruz Gonzalez, Claudia ^d   Andrade Ortega, Lilia ^e   Vera Lastra, Olga ^d   Salazar Páramo, Mario ^a   Prieto Parra, Rosa E ^d   Gonzalez Lopez, Laura ^d   Gamez Nava, Jorge I ^d   Ramírez Sánchez, Hermes U ^a   Chan, Jason Y F ^b   Ross, Steven J ^b   Chan, Edward K L ^f   Vázquez Del Mercado, Mónica ^a,g  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^f UNIVERSITY OF FLORIDA   (United States)

^g HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CREATINE KINASE; MI 2 AUTOANTIBODY; P155 AUTOANTIBODY; UNCLASSIFIED DRUG; AUTOANTIGEN; CHD4 PROTEIN, HUMAN; HISTONE DEACETYLASE; MI-2 ANTIBODIES; P140 AUTOANTIGEN, HUMAN;

ADULT; ANTIBODY TITER; ARTICLE; COMPARATIVE STUDY; DERMATOMYOSITIS; FEMALE; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEXICO; ONSET AGE; BLOOD; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; PREVALENCE;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOPRECIPITATION; MALE; MEXICO; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MIDDLE AGED; PREVALENCE;

EID: 84875689792     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4207     Document Type: Article

References (32)

1. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep 2008, 10:333-340. 10.1007/s11926-008-0053-2, 18662515.
2. Nakashima R, Mimori T. Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies. Int J Clin Rheumatol 2010, 5:523-536.
3. Satoh M, Vazquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009, 19:219-228. 10.1007/s10165-009-0155-3, 2876095, 19277826.
4. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996, 39:1507-1518. 10.1002/art.1780390910, 8814062.
5. Shamim EA, Rider LG, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, Burgos-Vargas R, Vazquez-Mellado J, Alcocer-Varela J, Salazar-Paramo M, Kutzbach AG, Malley JD, Targoff IN, Garcia-De la Torre I, Miller FW. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002, 46:1885-1893. 10.1002/art.10358, 12124873.
6. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003, 48:2285-2293. 10.1002/art.11090, 12905483.
7. O'Hanlon TP, Rider LG, Schiffenbauer A, Targoff IN, Malley K, Pandey JP, Miller FW. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008, 58:3239-3246. 10.1002/art.23899, 2682358, 18821675.
8. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, Tincani A, Ross SJ, Chan JY, Pauley BA, Chan EK, Satoh M. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012, 14:R97. 10.1186/ar3822, 3446471, 22546500.
9. Love LA, Burgess SH, Hill PC, Oddis CV, Medsger TA, Leff RL, Plotz PH, Reveille JD, Arnett FC, Targoff IN, Miller FW. Geographical and seasonal clustering in the onset of idiopathic inflammatory myopathy (IIM) in groups defined by myositis-specific autoantibodies (MSA). Arthritis Rheum 1992, 35:S40.
10. Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, Chin Loy A, Chan EK, Reeves WH, Satoh M. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006, 54:2004-2009. 10.1002/art.21883, 16732549.
11. Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther 2011, 13:R214. 10.1186/ar3547, 3334667, 22192091.
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347. 10.1056/NEJM197502132920706, 1090839.
13. Satoh M, Langdon JJ, Hamilton KJ, Richards HB, Panka D, Eisenberg RA, Reeves WH. Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. J Clin Invest 1996, 97:2619-2626. 10.1172/JCI118711, 507349, 8647956.
14. Chan EK, Hamel JC, Buyon JP, Tan EM. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest 1991, 87:68-76. 10.1172/JCI115003, 294993, 1985112.
15. Yamasaki Y, Narain S, Hernandez L, Barker T, Ikeda K, Segal MS, Richards HB, Chan EK, Reeves WH, Satoh M. Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Res Ther 2006, 8:R111-120. 10.1186/ar2000, 1779422, 16846524.
16. Nilasena DS, Trieu EP, Targoff IN. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum 1995, 38:123-128. 10.1002/art.1780380119, 7818561.
17. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682-3689. 10.1002/art.22164, 17075819.
18. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K. Myositis-specific anti-155/140 autoantibodies target transcriptional intermediary factor 1 family proteins. Arthritis Rheum 2012, 64:513-522. 10.1002/art.33403, 21987216.
19. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:859-890. viii, 10.1016/S0889-857X(02)00032-7, 12506776.
20. Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007, 56:3132-3137. 10.1002/art.22862, 17763420.
21. Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK. Autoimmune targeting of key components of RNA interference. Arthritis Res Ther 2006, 8:R87. 10.1186/ar1959, 1779426, 16684366.
22. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985, 28:796-803. 10.1002/art.1780280711, 2409985.
23. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998, 95:279-289. 10.1016/S0092-8674(00)81758-4, 9790534.
24. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
25. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257-1266.
26. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123. 10.1136/ard.60.2.116, 1753477, 11156543.
27. Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger TA, Reveille JD, Arnett FC, Targoff IN, Miller FW. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum 2009, 60:2499-2504. 10.1002/art.24702, 2855681, 19644877.
28. Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 2008, 283:34976-34982. 10.1074/jbc.M805383200, 2596409, 18922793.
29. Salazar-Flores J, Dondiego-Aldape R, Rubi-Castellanos R, Anaya-Palafox M, Nuno-Arana I, Canseco-Avila LM, Flores-Flores G, Morales-Vallejo ME, Barojas-Perez N, Munoz-Valle JF, Campos-Gutierrez R, Rangel-Villalobos H. Population structure and paternal admixture landscape on present-day Mexican-Mestizos revealed by Y-STR haplotypes. Am J Hum Biol 2010, 22:401-409. 10.1002/ajhb.21013, 19967759.
30. Hanis CL, Hewett-Emmett D, Bertin TK, Schull WJ. Origins of U.S. Hispanics. Implications for diabetes. Diabetes Care 1991, 14:618-627. 10.2337/diacare.14.7.618, 1914811.
31. Satoh M, Ceribelli A, Chan EK. Role of environmental factors in autoantibody production - importance of a detailed analysis in a small cohort. Arthritis Res Ther 2012, 14:109. 10.1186/ar3739, 3392830, 22380573.
32. The Global Solar UV Index., http://www.grida.no/graphicslib/detail/the-global-solar-uv-index_1394.